Effects of MIND Diet on Brain Fog, Stress, and Sleep Quality in Young Adults (Young Mind)

November 19, 2026 updated by: Halic University

The Effect of a MIND Diet-Based Nutritional Intervention on Brain Fog, Perceived Stress, Sleep Quality, and Selected Biochemical Findings in Young Adults

This study aims to evaluate the effects of a MIND diet-based nutritional intervention on brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. It will also compare the effects of the MIND diet with those of the Mediterranean diet and usual dietary habits.

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is a dietary pattern that combines elements of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets. It emphasizes the consumption of green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, poultry, and olive oil, while limiting foods high in saturated fat, processed foods, and sweets. The Mediterranean diet similarly emphasizes plant-based foods, olive oil, whole grains, legumes, vegetables, fruits, nuts, and fish.

Young adults aged 18-35 years who meet the study eligibility criteria will be included. Participants will be randomly assigned to one of three groups: a MIND diet intervention group, a Mediterranean diet intervention group, or a control group.

Participants in the MIND diet group will receive nutritional guidance and follow a MIND diet-based dietary plan for 12 weeks. Participants in the Mediterranean diet group will receive nutritional guidance and follow a Mediterranean diet-based dietary plan for the same period. Participants in the control group will continue their usual dietary habits without receiving a structured dietary intervention during the study period.

Assessments will be conducted at baseline and at the end of the 12-week intervention. These assessments will include brain fog, perceived stress, sleep quality, dietary intake, and anthropometric measurements. Brain fog, perceived stress, and sleep quality will be evaluated using standardized assessment questionnaires. Dietary intake and adherence to the assigned dietary patterns will also be monitored throughout the intervention.

Selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, liver enzymes, uric acid, urea, and creatinine, will be assessed through blood samples.

The study will investigate whether following the MIND or Mediterranean dietary pattern for 12 weeks is associated with changes in brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. The findings may contribute to a better understanding of the relationship between dietary patterns and cognitive, psychological, sleep-related, and metabolic health.

Study Overview

Detailed Description

### Detailed Description

The MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet is a dietary pattern developed by combining elements of the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet. It emphasizes foods that may support brain and metabolic health, including green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, and poultry, while limiting the consumption of foods high in saturated fat, processed foods, sweets, and fried foods.

The Mediterranean diet is characterized by a high intake of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil, with regular consumption of fish and moderate consumption of other animal-based foods. Both dietary patterns emphasize minimally processed, nutrient-dense foods and a balanced dietary approach.

This study is designed as a 12-week, randomized, parallel-group, three-arm interventional trial involving young adults aged 18-35 years. The study will compare the effects of a MIND diet-based nutritional intervention and a Mediterranean diet-based nutritional intervention with a control group that will maintain its usual dietary habits.

Participants assigned to the MIND diet group will receive individualized nutritional counseling and a dietary plan based on MIND diet principles. The intervention will emphasize the regular consumption of green leafy vegetables, other vegetables, berries, nuts, legumes, whole grains, fish, and poultry, while encouraging the limitation of foods associated with lower adherence to the MIND dietary pattern.

Participants assigned to the Mediterranean diet group will receive individualized nutritional counseling and a dietary plan based on Mediterranean diet principles. The intervention will emphasize vegetables, fruits, legumes, whole grains, olive oil, nuts, seeds, and fish as important components of daily and weekly food consumption.

Dietary plans will be individualized according to participants' age, sex, physical activity level, and estimated energy requirements. Participants in both intervention groups will receive nutritional guidance throughout the 12-week study period. Dietary adherence and food consumption will be monitored at 15-day intervals using dietary records, including three-day food consumption records, and adherence assessments.

Participants in the control group will not receive a structured dietary intervention and will be asked to maintain their usual dietary habits during the study period.

Baseline assessments will be performed before the dietary interventions begin. At the end of the 12-week intervention, the assessments will be repeated to evaluate changes over time.

The primary areas of assessment include brain fog, perceived stress, and sleep quality. Brain fog will be assessed using the Brain Fog Scale, perceived stress using the Perceived Stress Scale (PSS-10), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

Anthropometric and body composition measurements will also be obtained, including body weight, height, body mass index (BMI), and body composition assessed by bioelectrical impedance analysis.

Fasting blood samples will be collected to evaluate selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid, urea, and creatinine.

The study aims to determine whether a 12-week MIND diet-based or Mediterranean diet-based nutritional intervention is associated with changes in brain fog, perceived stress, sleep quality, anthropometric measurements, and selected biochemical parameters in young adults. Comparisons between the three study groups will be used to evaluate the potential effects of the dietary interventions.

Study Type

Interventional

Enrollment (Estimated)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18-35 years.
  • Willingness to participate in the study and provide written informed consent.
  • Ability and willingness to follow the assigned dietary intervention for 12 weeks.
  • Ability to complete dietary records and study questionnaires.

Exclusion Criteria:

  • Presence of chronic diseases requiring a specific medical nutrition therapy.
  • Pregnancy or breastfeeding.
  • Food allergies or intolerances that prevent adherence to the study diets.
  • Following a medically prescribed or restrictive diet.
  • Regular use of medications that may significantly affect the study outcomes.
  • Any condition that may interfere with participation in the study or adherence to the intervention.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mind Diet Group

Participants will receive a 12-week dietary intervention based on the MIND diet.

Participants will receive a 12-week dietary intervention based on the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Experimental: Mediterranean Diet Group

Participants will receive a 12-week dietary intervention based on the Mediterranean diet.

Participants will receive a 12-week dietary intervention based on the Mediterranean diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

No Intervention: Control Group

Participants will not receive a specific dietary intervention during the 12-week study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Brain Fog Scale Score
Time Frame: 12 weeks

Brain fog will be assessed using the 23-item Brain Fog Scale. The total score ranges from 0 to 92. Higher scores indicate more severe brain fog symptoms and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Pittsburgh Sleep Quality Index Scores
Time Frame: 12 weeks

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Perceived Stress Scores
Time Frame: 12 weeks

Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40. Higher scores indicate higher levels of perceived stress and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Fasting Blood Glucose Levels
Time Frame: 12 weeks

Fasting blood glucose levels will be measured using standard biochemical laboratory methods after overnight fasting. Changes in fasting blood glucose levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Total Cholesterol Levels
Time Frame: 12 weeks

Serum total cholesterol levels will be measured using standard biochemical laboratory methods. Changes in total cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Low-Density Lipoprotein (LDL) Cholesterol Levels
Time Frame: 12 weeks

Serum low-density lipoprotein (LDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in LDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in High-Density Lipoprotein (HDL) Cholesterol Levels
Time Frame: 12 weeks

Serum high-density lipoprotein (HDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in HDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Triglyceride Levels
Time Frame: 12 weeks

Serum triglyceride levels will be measured using standard biochemical laboratory methods. Changes in triglyceride levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Aspartate Aminotransferase (AST) Levels
Time Frame: 12 weeks

Serum aspartate aminotransferase (AST) levels will be measured using standard biochemical laboratory methods. Changes in AST levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Alanine Aminotransferase (ALT) Levels
Time Frame: 12 weeks

Serum alanine aminotransferase (ALT) levels will be measured using standard biochemical laboratory methods. Changes in ALT levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Uric Acid Levels
Time Frame: 12 weeks

Serum uric acid levels will be measured using standard biochemical laboratory methods. Changes in serum uric acid levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Urea Levels
Time Frame: 12 weeks

Serum urea levels will be measured using standard biochemical laboratory methods. Changes in serum urea levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Creatinine Levels
Time Frame: 12 weeks

Serum creatinine levels will be measured using standard biochemical laboratory methods. Changes in serum creatinine levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ahmet Murat Günal, PhD, Haliç University
  • Principal Investigator: Murat Baş, PhD, Acibadem University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 19, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 19, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared with other researchers due to privacy and confidentiality considerations. Data will be used solely for the purposes of this study and will be handled in accordance with applicable data protection regulations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe